Copyright Bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world The downturn at Novo Nordisk A/S could deal a further blow to Danish consumer confidence, with the drugmaker’s slumping shares threatening to deepen pessimism and cloud the economy’s real strength, according to Denmark’s fiscal watchdog. The pharmaceutical giant, whose obesity and diabetes drugs have long fueled Denmark’s growth, earlier this year cut its 2025 forecast, leading to “substantial” declines in the local stock market, the Danish Economic Councils said in a report on Tuesday. Novo shares have tanked more than 40% in 2025, dragging the Copenhagen benchmark index down to make it one of Europe’s worst performers this year.
